Table 1.
Baseline characteristics of KTRs explored
| Baseline Characteristics | KTRs, n=45 |
|---|---|
| Age, yr | 63.5±16.3 |
| Sex (M/W), n | 23/22 |
| Diabetes mellitus, n (%) | 10 (22.2) |
| Hypertension, n (%) | 36 (80) |
| BMI, kg/m2 | 26.2±4.7 |
| Time from transplantation, yr | |
| Median (range) | 6.9 (0.22–30.2) |
| Immunized KTR, n (%) | 12 (26.7) |
| Median PRA class I | 6 |
| Median PRA class II | 14.5 |
| Previous history of rejection, n (%) | 1 (2.2) |
| eGFR, ml/min per 1.73 m2 | 43.3±15.7 |
| P/C ratio, g/g | 0.26±0.06 |
| Lymphocytes count, per mm3 | |
| CD3+ | 892±476 |
| CD4+ | 447±263 |
| CD8+ | 397±297 |
| Induction therapy for KT, n (%) | |
| ATG | 18 (40) |
| Anti–R-IL2 | 27 (60) |
| IS regimen, n (%) | |
| Tacrolimus | 24 (53.3) |
| Cyclosporin | 8 (17.8) |
| MMF | 37 (82.2) |
| AZA | 4 (8.9) |
| Everolimus | 3 (6.7) |
| Belatacept | 10 (22.2) |
| Steroids | 21 (46.7) |
M, men; W, women; BMI, body mass index; PRA, panel reactive antibodies; P/C, proteinuria/creatininuria; KT, kidney transplantation; ATG, antithymoglobuline; R-IL2, IL-2 receptor; IS, immunosuppressive; MMF, mycophenolate mofetil; AZA, azathioprine.